Ads
related to: myotonic muscular dystrophy- Request A Representative
Learn More About This
Treatment Option For Your Patients
- Dosing & Administration
Learn About Dosing &
Administrating This Treatment
- About This Treatment
Learn More About This Treatment
Option For Your Patients
- How This Treatment Works
Watch The Video To See How
This Treatment Option Works
- Stay Informed
Sign Up For Updates With The
Latest Information
- Physician Support
Support Resources To Help Get Your
Patients Started
- Request A Representative
Search results
Muscular dystrophy prevention, outlook, and slowing progression
Medical News Today· 4 days agoA person may inherit the genetic changes responsible for muscular dystrophy. Muscular dystrophies...
The Petri Dish: Dyne’s public offering, Kronos’ new CFO - Boston Business Journal
The Business Journals· 4 days agoAt the start of this week, Waltham’s Dyne Therapeutics Inc. had positive news to share on two...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WKBN 27 Youngstown· 6 days agoAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...
Arrowhead Pharma maintains $62 stock PT, overweight rating at Piper Sandler By Investing.com
Investing.com· 3 days agoThe firm's stance comes as Arrowhead recently held a Research and Development Day focusing on their...
Up 165% This Year, Will Dyne Therapeutics Continue Its Stellar Run?
Forbes· 6 days agoThis move came in after the company released a positive clinical trial data for its experimental...
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Zacks· 7 days agoDyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
Jefferies Financial Group Increases Dyne Therapeutics (NASDAQ:DYN) Price Target to $42.00
ETF DAILY NEWS· 6 days agoDyne Therapeutics (NASDAQ:DYN – Get Free Report) had its target price boosted by research analysts at Jefferies Financial Group from $36.00 to $42.00 in a report issued on Monday, Benzinga reports ...
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
InvestorPlace· 5 days agoMomentum trading is one of my favorite strategies. Legendary trader Mark Minervini, who won the U.S. investing championship in 1997 and 2021, used momentum trading strategies to win. Traders ...
Dipal Doshi Sells 1,800 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock
ETF DAILY NEWS· 6 days agoEntrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,800 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold ...
Ads
related to: myotonic muscular dystrophy